海外の治験の状況「1」での検索結果
185件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Recruiting
- Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
- Glioblastoma
- Argentina, Australia, Brazil, Canada, Chile, Colombia, Czech Republic, Greece, Hungary, India, Mexico, New Zealand, Peru, Poland, Serbia, Taiwan, Thailand, United States of America
- 2012-07-24
Recruiting
- Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6
- Hepatitis C Virus (HCV)
- Austria, Belgium, France, Greece, Israel, Italy, Poland, Portugal, Switzerland
- 2017-10-03
Recruiting
- Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
- Non-small Cell Lung Cancer
- Austria, France, Georgia, Ireland, Italy, Korea, Republic of, Lithuania, Netherlands, Poland, Russian Federation, Slovakia, Thailand, Ukraine, United States
- 2018-01-10
Recruiting
- A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
- Crohn's Disease
- American Samoa, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Serbia, Singapore, Slovakia, South Africa, Spain, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2017-04-04
Recruiting
- A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989
- Crohn's Disease
- American Samoa, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Russian Federation, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2017-04-04
Recruiting
- Efficacy and Safety Study of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)
- Crohn's Disease
- Australia, Austria, Belgium, Bulgaria, Croatia, Estonia, Germany, Hungary, Japan, Korea, Republic of, Lithuania, Netherlands, Poland, Slovakia, Spain, Ukraine, United States
- 2018-07-24
Recruiting
- A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Crohn's Disease Who Completed the Studies M14-431 or M14-433
- Crohn's Disease
- American Samoa, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2017-11-15
Recruiting
- Phase III multicenter, double-blind, randomized, parallel-group study to evaluate safety and efficacy of Hercules plus Taxane Herceptin® plus Taxane as First Line therapy in Her2-Positive Metastatic Breast cancer.
- Drug will be tested in HER and MBC patients
- Argentina, Austria, Brazil, Bulgaria, Canada, Chile, Czech Republic, Egypt, France, Georgia, Germany, Greece, Hungary, India, Latvia, Lebanon, Mexico, Peru, Philippines, Poland, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, United States of America
- 2014-12-30
Recruiting
- A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
- Metastatic Castrate Resistant Prostate Cancer;C61 - Malignant neoplasm of prostate
- Austria, Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, France, Germany, Hungary, Italy, Latvia, Netherlands, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Turkey, United Kingdom, United States
- 2014-11-13
Recruiting
- Study To assess the safety and tolerability of AGEN1884 administered in combination with pembrolizumab as a first-line treatment of subjects with metastatic Non Small Cell Lung Cancer (NSCLC).
- Non Small Cell Lung Cancer
- Australia, New Zealand
- 2017-07-20